• FDA Provides Emergency Use Authorisation for Serological Test to Identify COVID-19 Antibodies

Laboratory Products

FDA Provides Emergency Use Authorisation for Serological Test to Identify COVID-19 Antibodies

May 11 2020

PerlinElmer Inc has announced that the US Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for Euroimmun’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.

Serological tests detect antibodies in the blood and are detected when an immune reaction to the pathogen has already taken place. These tests can determine who had previously been infected with COVID-19 (2-4 weeks or more prior to testing) and may have developed immunity. How long antibodies last and whether they are protective is being actively studied. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) has 99% specificity and 100% sensitivity after 21 days following the onset of symptoms.

“Leading with science is a fundamental part of our DNA at PerkinElmer, and the Euroimmun team recognised early on that understanding the pathogenesis of COVID-19 from a cellular biology level is paramount to developing a highly accurate and reliable antibody test,” said Prahlad Singh, President and Chief Executive officer, PerkinElmer. “As a result, the antigen used in the Euroimmun Anti-SARS-CoV-2 ELISA (IgG), the spike protein S1 domain, is more likely to reflect virus neutralising antibodies than antibodies to N capsid nucleoprotein. This is also supported by the fact that most of the COVID-19 vaccine development programs in the US and worldwide have chosen the spike protein as their target.”

“It is possible that 50% or more of people who have been infected with COVID-19 might not display symptoms, making it difficult to identify those who have previously contracted COVID-19,” said Prahlad Singh. “That’s why serological testing that utilises an antigen highly specific to SARS-CoV-2 is such an important tool in understanding how pervasive this virus is.”

Euroimmun has the capacity to manufacture millions of assays per month. Since March, it has already started shipping its Anti-SARS-CoV-2 ELISA (IgG) to leading laboratories across the globe. Euroimmun intends to further build production capacity to meet heightened demand. 

More information online


Digital Edition

Lab Asia 29.4 - August 2022

August 2022

In This Edition Chromatography - Automated Sample Preparation:The Missing Hyphen to Hypernation - New Low Volume Air Sampler for PFAS Analysis - Analytical Intelligence Starts with the Samp...

View all digital editions

Events

ACS National Meeting & Expo, Fall 2022

Aug 21 2022 Chicago, IL, USA & Online

ACHEMA 2022 - NEW DATES

Aug 22 2022 Frankfurt, Germany

IMSC 2022

Aug 27 2022 Maastricht, Netherlands

EuCheMS Chemistry Congress

Aug 28 2022 Lisbon, Portugal

Medical Fair Asia 2022

Aug 31 2022 Singapore

View all events